Related Experiment Video
Updated: Jun 20, 2026

Quantitative Structure-Activity Relationship, Activity Prediction, and Molecular Dynamics of Non-nucleotide Reverse Transcriptase Inhibitors
Published on: May 9, 2025
Pyrazole NNRTIs 4: selection of UK-453,061 (lersivirine) as a development candidate
Charles E Mowbray1, Catherine Burt, Romuald Corbau
1Department of Discovery Chemistry, Pfizer Global Research and Development, Sandwich, Kent CT13 9NJ, UK. Charles.Mowbray@Pfizer.Com
Abstract:
We prepared three discreet cohorts of potent non-nucleoside HIV reverse transcriptase inhibitors (NNRTIs) based on the recently reported 3-cyanophenoxypyrazole lead 3. Several of these compounds displayed very promising anti-HIV activity in vitro, safety, pharmacokinetic and pharmaceutical profiles. We describe our analysis and conclusions leading to the selection of alcohol 5 (UK-453,061, lersivirine) for clinical development.
Related Concept Videos
Antiviral Nucleoside Inhibitors
Inhibitors Of Virion Release
Inhibitors of Viral Protein Synthesis
Inhibitors of Virion Maturation and Assembly
Subviral Agents
Antiprotozoal Agents

